Company
ORISDX
Detect oral cancer early with Oro Lesion, a non-invasive salivary DNA test that guides timely interventions and improves patient outcomes.
Also known as OrisDX Inc
- Business model
- B2B
- Legal name
- OrisDX Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Saliva-based multiomic diagnostic platform for oral cancer and HPV
Funding snapshot
- Total raised
- $2.8MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $2.8M2025-05-23
Funding rounds
- Round, 2025
- $2.8M2025-05-23, SEC form D sold, 25 investors
Loading relationship preview